Rayner announced in a press release that it has secured US Food and Drug Administration (FDA) 510(k) clearance for Sophi, a Swiss-engineered phacoemulsification system.

According to the company, Sophi includes features that are designed to meet the demands of ASCs, office-based surgery, and US hospital networks—such as triple pump fluidics (both peristaltic and venturi), an intuitive user interface, and wireless power concept. In addition, the company said that surgeons and clinical teams can benefit from faster setup, quicker patient turnover, and greater mobility, without sacrificing patient safety.

“US surgeons deserve an innovative alternative to conventional phaco technology, and Sophi delivers that," commented Tim Clover, CEO, Rayner, in the press release. "Clinics worldwide tell us they’re running more efficiently and cutting cost and waste, so we’re looking forward to bringing these benefits to surgeons across the US through our new team of surgical equipment specialists.”

Rayner also pointed out that a recent position paper estimated a 307kg reduction in discarded plastic per 1,000 cataract surgeries using Sophi’s day cassette option. Rayner said it is committed to bringing this feature to the US market to help support the industry’s drive to reduce surgical waste and carbon footprint.